Study findings presented at ESMO 2018 Congress revealed the effect of a shorter, 9-week course of trastuzumab on disease-free survival (DFS) and cardiac toxicity in women with HER2-positive breast cancer.
Trastuzumab and certain chemotherapy treatments can increase patient risk of heart failure.
Researchers explored whether adding trastuzumab to carboplatin and paclitaxel would improve survival outcomes for patients with advanced/recurrent disease with overexpressed HER2/neu.
Biosimilars and originator trastuzumab neoadjuvant therapy had a comparable effect on pathologic complete response rates.
HER-2 enriched subtype predicts for HER2 blockade benefit with lapatinib and trastuzumab
Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.
Researchers found wide variances in the cost of breast cancer chemotherapy, depending on the course of treatment selected.
MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.
Patients undergoing treatment for breast cancer with trastuzumab-containing regimens need to be monitored for heart damage regardless of age.
Women with the HER2-enriched type of HER2-positive breast cancer had the highest rate of immune response to treatment with trastuzumab, with a significant increase after just 1 dose of the drug.
